The Precision Peptide Company Inc. Announces Development of Needle-Free Tirzepatide Transdermal Patch

Precision Peptide touts a patch concept, but offers no proof or financials yet.

What the company is saying

Precision Peptide Company claims it is developing a tirzepatide-based transdermal patch in the United States, positioning this as a needle-free, room-temperature-stable alternative to current injectable GLP-1 therapies. The announcement repeatedly emphasizes the global GLP-1 market size, citing figures of US$62–66 billion in 2025 and a projected US$185.3 billion by 2033, as well as Eli Lilly's US$36.5 billion in 2025 sales for Mounjaro and Zepbound. The company frames its patch as a solution to barriers like needle aversion, cold-chain logistics, and sharps disposal, referencing a 20–30% needle-fear prevalence among adults aged 20–40. Language throughout is aspirational, focusing on intended features and anticipated demand, with no mention of clinical data, regulatory submissions, or commercialization timelines. The company asserts all development and manufacturing will occur in the U.S. to FDA standards, but provides no evidence of compliance or progress. CEO Pratap Sandhu is named, but no institutional partnerships or external validation are referenced.

What the data suggests

The only concrete data relates to the broader GLP-1 market and competitor performance, not Precision Peptide's own operations. No financial statements, revenue figures, cash balances, or expense disclosures are provided. The company confirms it is developing the patch and that some products are manufactured in an approved U.S. facility, but does not specify whether these include the tirzepatide patch or other products. All claims about the patch's benefits, regulatory compliance, and market demand are forward-looking and unsupported by disclosed evidence. There is no data on clinical progress, manufacturing scale, or regulatory milestones. The gap between the company's narrative and the disclosed facts is wide: market size and competitor sales are used to imply opportunity, but there is no indication Precision Peptide is capturing any share of this market. Data quality is insufficient for any assessment of financial trajectory or operational execution.

Analysis

The announcement is highly positive in tone, emphasizing the company's development of a tirzepatide-based transdermal patch and the large, rapidly growing GLP-1 market. However, nearly all key claims are forward-looking, describing intended product features, anticipated regulatory compliance, and projected market demand, with no evidence of regulatory progress, clinical validation, or commercial readiness. The only realised facts are that development is underway and that some products are manufactured and distributed, but there is no disclosure of revenue, profitability, or even product launch timelines. The capital intensity flag is triggered by references to U.S.-based development and manufacturing to FDA standards, which implies significant investment, yet there is no indication of immediate earnings or near-term milestones. The gap between narrative and evidence is wide: the company leverages large market statistics and aspirational language to imply opportunity, but provides no measurable progress or financial data.

Risk flags

• ●Execution risk is high because the company has not disclosed any clinical data, regulatory filings, or technical validation for its tirzepatide patch. Without evidence of progress through the FDA process or demonstration of room-temperature stability, the path to approval and commercialization remains speculative.
• ●Financial transparency is lacking, as there are no disclosures of revenue, cash position, or funding sources. This omission makes it impossible to assess whether the company can sustain long-term product development or absorb the capital intensity implied by U.S.-based manufacturing to FDA standards.
• ●Market adoption risk is significant: while the company cites large GLP-1 market figures and rising usage rates, it provides no evidence of customer interest, partnership discussions, or competitive differentiation. The absence of any signed agreements or external endorsements suggests the company is still at a concept or early development stage.

Bottom line

This announcement is a high-level concept pitch for a tirzepatide transdermal patch, not evidence of technical, regulatory, or commercial progress. The company relies on large market statistics and competitor sales to imply opportunity, but provides no proof it can deliver or capture value. No financials, clinical data, or regulatory milestones are disclosed, leaving investors with no basis to assess execution or funding risk. CEO Pratap Sandhu's involvement is stated, but there are no institutional partnerships or external validation. For this to become actionable, the company would need to show concrete progress—such as clinical results, regulatory filings, or commercial agreements. Until then, the most important takeaway is that this is an aspirational narrative, not a near-term investment catalyst.

Announcement summary

(CSE: BPC) (OTCQB: PNGAF) The Precision Peptide Company announced it is developing a tirzepatide-based transdermal patch delivery system in the United States as an addition to its advancing product lineup. The global GLP-1 market is highlighted at US$62 to 66 billion in 2025, projected to reach US$185.3 billion by 2033. Eli Lilly's injectable tirzepatide products Mounjaro and Zepbound generated US$36.5 billion in sales in 2025. Approximately 11% of U.S. adults have now used GLP-1 medications as of mid-2026, more than triple the rate measured two years earlier. The company's transdermal patch is being developed to be needle-free and room-temperature stable, eliminating the need for injections and cold-chain storage. All of the company's development and intended manufacturing will be conducted in the United States in compliance with applicable regulatory requirements, including FDA standards. Products are manufactured in an approved U.S. facility and distributed across North America.

Disagree with this article?